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Abstract
Background:  Gene duplication and exonization of intronic transposed elements are two
mechanisms that enhance genomic diversity. We examined whether there is less selection against
exonization of transposed elements in duplicated genes than in single-copy genes.
Results: Genome-wide analysis of exonization of transposed elements revealed a higher rate of
exonization within duplicated genes relative to single-copy genes. The gene for TIF-IA, an RNA
polymerase I transcription initiation factor, underwent a humanoid-specific triplication, all three
copies of the gene are active transcriptionally, although only one copy retains the ability to generate
the TIF-IA protein. Prior to TIF-IA triplication, an Alu element was inserted into the first intron. In
one of the non-protein coding copies, this Alu is exonized. We identified a single point mutation
leading to exonization in one of the gene duplicates. When this mutation was introduced into the
TIF-IA coding copy, exonization was activated and the level of the protein-coding mRNA was
reduced substantially. A very low level of exonization was detected in normal human cells.
However, this exonization was abundant in most leukemia cell lines evaluated, although the
genomic sequence is unchanged in these cancerous cells compared to normal cells.
Conclusion: The definition of the Alu element within the TIF-IA gene as an exon is restricted to
certain types of cancers; the element is not exonized in normal human cells. These results further
our understanding of the delicate interplay between gene duplication and alternative splicing and of
the molecular evolutionary mechanisms leading to genetic innovations. This implies the existence
of purifying selection against exonization in single copy genes, with duplicate genes free from such
constrains.
Background
The human and mouse genome sequencing projects
revealed that 99% of human genes have a homolog or an
ortholog in mouse, with an average of 88% conservation
in the coding sequence [1]. This suggests that other factors
must contribute to the phenotypic differences between
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human and mouse. Gene duplication and alternative
splicing are two fundamental mechanisms that shape
genome evolution. Alternative splicing acts at the level of
mRNA processing, whereas gene duplication affects
genomic DNA. Gene duplication can also operate at the
level of RNA via retroposition, which has been shown to
generate functional intronless duplicates of entire genes
[2-5]. The contributions of these two processes to the pro-
teome variability are substantially different [6,7].
Duplication of existing genes is an important mechanism
for generating new genes while maintaining the original
[8]. Gene duplication gives rise to a state of genetic redun-
dancy, in which one of the newly formed gene copies
enters a period of reduced evolutionary pressure, allowing
entirely novel functional patterns to emerge. Selective
constraints ensure that one of the duplicates retains its
original function but the second copy is free from these
constraints and, thus, accumulates mutations. These
mutations can lead to a non-functional pseudogene that
may continue (during a transition period) to be expressed
at the RNA level; eventually the pseudogene accumulates
further mutations that inactivate its transcription [9].
Alternatively, the mutations may lead to a different
expression pattern or to neo-functionalization that
advances organism speciation [10]. Neo-functionaliza-
tion of duplicated genes was previously attributed to
amino acid sequence changes through sporadic mutations
or through changes in gene expression patterns [11-13].
Indeed, in plants whole genome duplication is associated
with speciation [12].
An average human gene is 28,000 nucleotides long and
consists of 8.8 exons of ~130 nucleotides each (excluding
terminal exons) that are separated by 7.8 introns [14].
RNA splicing is the process in which introns are removed
and exons are joined together to form a mature mRNA.
RNA splicing is carried out by the spliceosome, which is
comprised of more than 150 proteins and five snRNPs,
called U1, U2, U4, U5, and U6 [15]. Alternative splicing
generates multiple mRNA products from a single gene,
contributing to transcriptome and proteome diversity.
Alternative splicing is a possible mechanism for bridging
the gap between the gene count in an organism's genome
and its level of phenotypic complexity [16-18]. Up-to-date
estimates suggest that more than 60% of human genes
undergo alternative splicing [18]. About 80% of alterna-
tive splicing events change the encoded protein and ~15%
of genetic diseases are caused by mutations within splic-
ing regulatory elements [19]. There are four types of alter-
native splicing alternative 5' splice or 3' splice site
selection, exon skipping, and intron retention. Selection
of previously un-used splice sites can result in creation of
a new exon, which is alternatively spliced. Exonization is
essentially a birthing process of new exons from intronic
sequences.
In human, most of newly generated exons originate from
the primate-specific transposed element, Alu. Repetitive
DNA sequences are found in most organisms and, in
some, constitute a substantial fraction of the entire
genome (~46% in human). Various types of repetitive
DNA sequences are found within mammalian genomes
and have contributed to mammalian evolution [20]. The
Alu sequences are short interspersed elements (SINE) of
about 300 nucleotides in length, which are unique to pri-
mates [21-24]. Over the past 65 million years, the Alu
sequence has been amplified via an RNA-mediated trans-
position process to a copy number of 1.1 million, com-
prising an estimated 10% of the human genome [14,24-
27].
Seven hundred thousand Alu  elements exist within
intronic sequences; of these, 480,052 are found within
introns of protein coding genes, in both sense and anti-
sense orientations with respect to the mRNA precursor
[28,29]. The Alu element in the antisense orientation con-
tains most of the characteristics required for identification
as an exon by the splicing machinery. Alu exonization is
an evolutionary pathway that generates primate-specific
transcriptomic diversity [30].
Recent studies that examined the evolutionary trend of
alternative splicing after gene duplication revealed that
duplicate genes have fewer alternatively spliced forms
than single-copy genes (singletons) and that an inverse
correlation exists between the mean number of alternative
splice forms and the gene family size [31]. These results
suggest that there is a loss of alternative splicing in dupli-
cated genes after the duplication and that there is an asym-
metric evolution of alternative splicing after gene
duplication [32-34]. It seems that the duplication event
compensates for a reduced use of alternative splicing and
that gene duplication and alternative splicing do not
evolve independently [31,34].
In this study, we compared the level of de novo exonization
of transposed elements in duplicated genes with the level
in singletons. We employed a whole-genome bioinfor-
matic analysis, supported by in vivo analysis, to examine
whether duplicated genes exhibited a lower level of selec-
tion against exonization of transposed elements (TE). The
results suggest that alternatively spliced exons that origi-
nate from exonization of transposed elements are found
significantly more frequently in duplicated genes than in
singletons. In one of these genes, TIF-IA, the TE in one of
the duplicates, but not in the original, is exonized. We
identified the point mutation leading to the exonization.
When this mutation was inserted into the original gene, itBMC Molecular Biology 2007, 8:109 http://www.biomedcentral.com/1471-2199/8/109
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caused exonization that substantially reduced production
of the protein-coding mRNA. This implies that there was
selection against exonization in the original gene, whereas
the duplicate was free from such constraints. The exoniza-
tion in the duplicated gene occurs in some leukemia cells,
but not in normal cells, implying that changes in activity
or concentration of splicing factors [35] within leukemia
cells changes exon/intron recognition.
Results
Transposed elements more likely to be exonized in 
duplicated genes
Duplicated genes undergo relaxation of selective pressure
following duplication. The increase in mutational rate
leads to changes in the mRNA sequence in the duplicated
gene relative to the original [36,37]. In this study, we
investigated whether the relaxation in selective pressure
also leads to an increase in exonization of TEs in duplicate
genes compared with singletons. For this purpose, we
compiled a dataset of exons resulting from TE exoniza-
tions within the human genome [28]. These exons were
divided into two groups: those that reside within dupli-
cated genes and those that reside within singletons. Our
dataset of TE exonizations contains 1824 exons in 1388
different genes. We found 57 Alu exons in 45 duplicated
genes, 7 MIR (mammalian interspersed repeat) exons in 7
duplicated genes, 15 L1 (LINE-1) exons in 15 duplicated
genes, three L2 (LINE-2) exons in three duplicated genes,
15 LTR (long terminal repeat) exons in 12 genes, and
three DNA exons in three genes. Overall, we identified
100 TE exons in 77 duplicated genes, that is, an average of
1.3 TE exons per gene (the genes with numerous exoniza-
tions are listed in Table 1; also see Additional file 1). All
other TE exons (1724) reside in 1559 genes, that is, an
average of 1.1 exons per gene. The exonization rate within
duplicated genes was significantly higher than that in sin-
gletons (two-tailed Mann-Whitney p-value < 0.005).
Are these TE exonizations within duplicated genes part of
a neo-functionalization or a non-functionalization proc-
ess? Apparently, both trajectories are present within our
dataset. An example for neo-functionalization is the pri-
mate-specific duplication of the gene GON4L that gener-
ated the duplicated gene YY1AP1 [38,39]. The gene
YY1AP1 is functional and also has a new role as a co-acti-
vator, YY1; it also has different levels of expression within
human tissue relative to its duplicate [38,40]. Our exoni-
zation analysis revealed that YY1AP1 contains two differ-
ent Alu exonizations that do not exist within GON4L. One
of the exonizations results from the Alu that was inserted
prior to the gene duplication. The other resulted from an
insertion of an Alu element after the duplication and sub-
sequent exonization [41].
An example of non-functionalization and subsequent
pseudogenesis is found in the duplication of the NCF1
gene. NCF1 is one of the genes responsible for the chronic
granulomatous disease (CGD) and also contributes to
Table 1: Duplicated genes with multiple TE exonization
No. of 
exons
TE Gene Accession Description Dup. gene Dup. accession Dup. description
3A l u S x  A l u J o  
MER5A
SRPN NM_022807 small nuclear ribonucleo-
protein polypeptide N
SNRPB BC003530 small nuclear ribonucleo-
protein polypeptides B and 
B1
2 AluSx AluJb NCF1 
pseudo-gene
BC002816 neutrophil cytosolic factor 
1 pseudo-gene
NCF1 NM_000265 neutrophil cytosolic factor 1
2 AluSx AluJb YY1AP1 BC025272 YY1 associated protein GON4L BX648802 gon-4-like protein
2 AluSp MIR NSUN5C NM_148936 NOL1/NOP2/Sun domain 
family member 5C
NSUN5 NM_018044 NOL1/NOP2/Sun domain 
family, member 5
2 AluY AluJb RAP1A NM_001010935 RAP1A, member of RAS 
oncogene family
RAP1B NM_015646 RAP1B, member of RAS 
oncogene family
2 AluSx MSTA POLR2J2 BC086857 RPB11b1beta protein 
(DNA directed RNA 
polymerase II polypeptide J-
related)




ZNF611 NM_030972 zinc finger protein 611 ZNF701 NM_018260 zinc finger protein 701
2 AluSq AluSp ZNF702 NM_024924 zinc finger protein 702 ZNF137 NM_003438 zinc finger protein 137
3 MSTA MSTA 
MSTA
PMS2L14 AB017005 PMS2L14 protein. PMS2 NM_000533 PMS2 postmeiotic 
segregation increased 2 
isoform
2 AluJb AluY ZNF283 AK098175 zinc finger protein 283 ZNF420 NM_144689 zinc finger protein 420
2 AluJo L1MA9 ZNF678 NM_178549 zinc finger protein 678 ZNF479 AF277624 zinc finger protein 479
2 AluSx LTR49 PILRB NM_013440 paired immunoglobulin-like 
type 2 receptor beta
PVRIG NM_024070 poliovirus receptor related 
immunoglobulinBMC Molecular Biology 2007, 8:109 http://www.biomedcentral.com/1471-2199/8/109
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autoimmunity [42]. In human, the gene underwent tripli-
cation, the two duplicates are well characterized [43]. Our
analysis of TE exonization revealed that there was an Alu
exonization within the second intron of each of the two
pseudogenes. There is no evidence for this exonization
within the functional gene, even though the Alu element
is present within the intron of the functional gene as well.
Our dataset contains both exonization of TEs that were
inserted prior to gene duplication and those that were
inserted after gene duplication. Two of the Alu exoniza-
tions in duplicated genes in our dataset were shown to be
associated with cancerous tissues based on the tissue ori-
gin of their ESTs [28,44]; the Alu  exonization within
intron 2 of the gene YY1AP1, the aforementioned dupli-
cate of the gene GON4L [38]; and Alu exonization within
intron 6 of the gene ACAD9, a paralog of ACADVL (p-
value < 0.01).
TIF-IA gene underwent a hominidae-specific triplication
One of the genes from our bioinformatic analysis is tran-
scription initiation factor IA (TIF-IA). This transcription
initiation factor directs growth-dependent regulation of
RNA polymerase I. It is a 75-kDa protein and levels, or
activity, fluctuate in response to cell proliferation [45].
Genetic inactivation of the transcription factor TIF-IA
leads to nucleolar disruption, cell cycle arrest, and p53-
mediated apoptosis [46]. Therefore, TIF-IA is a key protein
in adapting cellular biosynthetic activities to cell growth
[47].
The gene that encodes TIF-IA is highly conserved from
yeast to human and is essential for cell survival. Align-
ment of the human cDNA of TIF-IA against the human
genome using Blat (UCSC Genome Browser [48])
revealed two imperfect copies of TIF-IA, which presuma-
bly resulted from gene duplication. The original copy of
TIF-IA gene (termed locus 15), as well as the two dupli-
cates (termed locus 28 and locus 21), are located on chro-
mosome 16. In addition, a processed pseudo-gene of TIF-
IA is located on chromosome 2, but is not transcribed
according to EST data.
The two duplicates of the gene were probably generated in
a sequential manner, as illustrated in Figure 1. Non-
homologous recombination was probably the mecha-
nism for the triplication, because all the copies are on the
same chromosome. In detail, the original gene from locus
15 was duplicated almost completely, except for the last
exon (exon 18), to locus 28. Next, a major deletion of
3,517 bp within the duplicate, which included exons 11
and 12, occurred. Then, locus 28 was duplicated to locus
21. This duplication was also incomplete, resulting loss of
the last three exons (exons 16 to 18). The deletion was
confirmed experimentally (data not shown).
The original TIF-IA gene and its two duplicates in the human genome Figure 1
The original TIF-IA gene and its two duplicates in the human genome. Exons and introns are marked with numbered boxes and horizontal lines, 
respectively. Splicing events between exon 1 and 2 are marked with dashed lines. Each of the TIF-IA genes is named according to its relative location on 
chromosome 16: that is, loci 15, 28, and 21. The relative levels of expression from each locus, as measured by DS Gene®, are given as percent of total TIF-
IA mRNA in P69 cells and shown on the left. Locus 15 is the original full-length gene, containing 18 exons, coding for a 75 kDa protein (651 aa) (see Addi-
tional file 3). The transcription start site is marked by an arrow above exon 1 and the stop codon by a stop sign above exon 18. The 3'UTR accounts for 
~47% of the mRNA molecule. The Alu element is located in intron 1. Locus 28 is a duplication of the original TIF-IA gene containing the promoter region 
of the original gene (marked by black box). A deletion of 768 nucleotides in the promoter region reduced its transcription activity. Also, this locus contains 
two additional deletions with respect to the original gene: a deletion of 3517 nucleotides between intron 10 and intron 12 (between LTR16A1 and Alu-Sg 
transposed elements) and a deletion of the last exon (exon 18). The last two exons of locus 28 probably originated following a duplication event of exons 
3 and 4 of BANP gene (96.6% sequence similarity). The complete BANP gene is also located on chromosome 16. The mRNA synthesized from that site 
has the potential to encode a protein of 514 aa according to a translation-prediction tool, using the same start codon as that of locus 15. A protein corre-
sponding to the predicted molecular weight was not detected by western blotting analysis (see Additional file 3). Locus 21 is presumably a duplication of 
locus 28, containing the exact major deletion as that of locus 28 and, in addition, a deletion downstream of exon 15. The last two exons originated from 
exonization events of LINE-LTR and Alu-Sq transposed elements. Alternative poly-adenylation signal in the last two exons is shown. Locus 21 has the 
potential to encode a 106 aa protein from the third AUG downstream from the transcription start site. The first AUG potentially encodes a 39-aa 
polypeptide. Analysis of ESTs and RT-PCR revealed that two RNA molecules are generated from locus 21, as shown in the lower panel (data not shown).BMC Molecular Biology 2007, 8:109 http://www.biomedcentral.com/1471-2199/8/109
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Blat of human mRNA on the chimpanzee genome sug-
gests that it also contains more than one copy of TIF-IA
gene. The original gene is located on chromosome 16, as
it is in the human genome. There are several regions of
homology to TIF-IA on chromosome 16 (in addition to
the WT gene), as well as a processed pseudogene on chro-
mosome 2b. It was difficult to determine the order and
pattern of duplication events in the chimpanzee genome
due to incomplete sequencing and the low level of
genome assembly; however, it is clear that the chimp
genome contains more than one copy of the TIF-IA gene
on the same chromosome.
Alignment of TIF-IA cDNA with the rhesus genome
revealed the presence of the original copy of the gene on
chromosome 20 and the processed pseudogene on chro-
mosome 12, but no duplications. Similar analysis on
other vertebrate genomes (C. familiaris, B. taurus, M. mus-
culus, R. norvegicus, G. gallus, X. tropicalis, D. rerio) and
non-vertebrate organisms (D. melanogaster, S. cerevisiae, S.
pombe, C. elegans) revealed that each had only a single
copy of TIF-IA gene. Therefore, we concluded that the
duplication of TIF-IA gene occurred after the human-
chimp-rhesus split but before the human-chimp split
between 4 and 25 million years ago.
Alu insertion in the first intron of TIF-IA
Examination of the TIF-IA genes revealed another intrigu-
ing event: An Alu element was inserted into the first intron
of the common ancestor of human, chimpanzee, and rhe-
sus (approximately 25 million years ago). This Alu was
inserted into another transposed element called L2,
located in intron 1 of the TIF-IA gene. We reconstructed
this scenario by examination of intron 1 of the TIF-IA gene
in other mammals. The L2 element was present in all
sequenced mammals except opossum. The insertion of
the Alu element into the L2 transposed element led to an
exonization in human. Based on alignment of ESTs to the
human genome (see Additional file 2), the 3' splice site
(3'ss) is donated by the L2 transposed element and two
alternative 5' splice site (5'ss) are selected, one donated by
the Alu sequence and the other by L2. We designated the
distal 5'ss, located in the Alu sequence as 5'ss-a, and the
proximal 5'ss, located in the L2 element, as 5'ss-b (Figure
2A and 2B). The overall steps that lead to the exonization
of that exon were as follows: (1) During primate evolu-
tion, an Alu-Sx element was inserted into an L2 retrotrans-
poson of the LINE family. (2) The sequence accumulated
mutations that caused exonization, leading to selection of
three different isoforms as demonstrated in Figure 2A.
This exon is termed L2-AEx.
Transcription and translation of the wild-type and 
duplicate TIF-IA genes
To examine whether the duplicates in the human genome
are active transcriptionally, we examined the putative pro-
moter regions of all three loci (Figure 1). The region of 1
kb upstream of the translation start codon of locus 15 has
96.5% identity to the corresponding upstream region of
locus 21. The 1-kb promoter region of locus 28 shows
similarity to that of locus 15; however, this putative pro-
moter contains a deletion of 768 bp that ends at position
-117 upstream of the potential translation start codon.
The many changes that occurred between the wild-type
gene and the two duplicates suggest that the duplicates are
not under selective pressure to encode functional protein.
Translation of the mRNA produced from the original TIF-
IA gene results in a 651-aa protein with a molecular
weight of 75 kDa. The duplicate at locus 28 potentially
encodes a 514-aa polypeptide chain, whereas the dupli-
cate at locus 21 potentially encodes a 39-aa polypeptide
using the genuine start codon or a 106-aa polypeptide
chain using the third ATG downstream of the transcrip-
tion start site (TSS). Polypeptides of sizes expected from
the duplicate loci were not detected by western blotting
analysis with polyclonal antibodies to the wild-type TIF-
IA protein (Additional file 3). Although proteins do not
appear to be generated from the duplicate genes, these
duplicates are active transcriptionally as indicated by ESTs
that derive from these loci. In addition, we measured the
relative mRNA levels based on nucleotide variation at cer-
tain positions between the loci. In P69 cells, mRNA from
the wild-type gene comprises about 80% of the mRNA
transcribed from the three loci and locus 28 and locus 21
constitute 3% and 17% of the mRNA, respectively (Figure
1).
Alu-exonization is exclusive to the TIF-IA duplicate in 
locus 21
EST analysis revealed that a large fraction of the L2-AEx-
containing ESTs originated from carcinogenic tissues,
such as Burkitt's lymphomas (Additional file 2). To exam-
ine the splicing patterns of exons 1 and 2 of the wild-type
gene and the two duplicates, we designed a pair of primers
to sequences in the flanking exons: 1 and 2 that are con-
served among all three loci, meaning all three copies will
be amplified simultaneously. We then performed RT-PCR
analysis of human cDNA from normal tissues and from
transformed cell lines. The major mRNA product from the
TIF-IA genes in most of normal tissues skips the Alu exon
and shows either no exonization or a negligible level of
exonization (Figure 3A). In two cell lines, 293T and BJ-1,
there was a substantial level of exonization (Figure 3A,
lanes 9 and lane 10, respectively). These results imply
that, for most of the tested cells, the exonization is a
minor or non-existent event. We did not detect any exoni-BMC Molecular Biology 2007, 8:109 http://www.biomedcentral.com/1471-2199/8/109
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Retrotransposition and exonization of an Alu element in the first intron of TIF-IA gene in locus 21 Figure 2
Retrotransposition and exonization of an Alu element in the first intron of TIF-IA gene in locus 21. (A) All mammalians genomes (except for 
opossum) contain a LINE element (L2) in intron 1 of TIF-IA gene. During primate evolution, an Alu element was inserted into L2. The L2 and Alu elements 
accumulated mutations leading to exonization (L2-AEx), in which a 3'ss and two alternative 5'ss are recognized by the splicing machinery. Three alterna-
tively spliced isoforms are generated following this exonization: (i) a skipping isoform with no L2-AEx; (ii) selection of a distal 5'ss (termed 5'ss-a), which 
generates a 180-nt L2-AEx; and (iii) selection of a proximal 5'ss (termed 5'ss-b), leading to exonization of a 370-nt L2-AEx (left to right, respectively). (B) 
Multiple alignment of TIF-IA splice sites and flanking regions in all three loci. Splice sites are marked with arrows on the top. Exonic and intronic sequences 
are in uppercase and lower case, respectively. Mutations relative to the original gene (locus 15) are highlighted in pink. 5'ss-a is the distal splice-site and 
5'ss-b is the proximal one.BMC Molecular Biology 2007, 8:109 http://www.biomedcentral.com/1471-2199/8/109
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zation of L2-AEx within chimpanzee blood cells, implying
that this exonization may be human specific (Figure 3A,
lane 17).
Next, we examined the exonization in 17 leukemia cell
lines by RT-PCR analysis and detected a high level of
exonization of both the short and long exonized form in
13 out of the 17 cell lines (76%). To specifically identify
the locus from which this exonization occurred, we
designed loci-specific primers and repeated the RT-PCR
analysis using the pair of primers that detects all three loci
and the locus-specific pairs of primers (Figure 3B). Only
locus 21 showed exonization in which 5'ss-a or of 5'ss-b
or both were selected and the ratio among the three iso-
forms varied significantly among the cell lines. Thus, there
was a low level or an absence of exonization in normal
human tissues and in epithelial cancer cell lines. In con-
trast, most leukemia cell lines exhibited a high level of
exonization. The exonization was restricted to one of the
duplicates (locus 21), but not to the original gene (locus
15). The cells that show exonization do not exhibit a
known common characteristic, such as a specific hemat-
opoietic lineage or mutations in a certain pathway or gene
that can explain the exonization in these cells but not in
Scanning of diverse normal human tissues, various human cell lines, and chimpanzee blood for Alu-exonization in the TIF-IA  genes Figure 3
Scanning of diverse normal human tissues, various human cell lines, and chimpanzee blood for Alu-exonization in the TIF-IA genes. (A) 
Low level of L2-AEx inclusion in normal tissues. cDNA from normal human tissues and cell lines was amplified by PCR analysis with primers directed to 
exons 1 and 2 of all three loci of TIF-IA genes. No evidence for Alu exonization was observed in chimpanzee blood. Splicing products were separated on 
1.5% agarose gel. The three mRNA isoforms are shown on the right; selected PCR products were eluted and sequenced. 293T are epithelial kidney cells. 
BJ-1 is normal human fibroblast cell line. HeLa are epithelial cervix cells with adenocarcinoma. HT 1080 originated from a fibrosarcoma. MCF-7 is a breast-
cancer cell line. P69 was derived by immortalization of human primary prostate epithelial cells. SK MEL-28 is a melanoma cell line and U2OS is an osteosa-
rcoma cell line. (B) Splicing patterns of L2-AEx in various human leukemia cell lines. Total cytoplasmic RNA was extracted from the indicated cell lines. 
Splicing products were separated on 1.5% agarose gel after RT-PCR analysis, using primers to exons 1 and 2 of all three loci of TIF-IA, to locus 15 alone, 
to locus 28 alone, and to locus 21 alone. The three mRNA isoforms are shown on the right. Selected splicing products were eluted from the gel and 
sequenced. Jurkat, Molt-3, and HSB are human T-cell leukemia cell lines. HL-60 is a myeloid cell line. Dami is a megakaryocytic AMKL (acute megakaryob-
lastic leukemia) non-Down syndrome (DS) cell line. U937 is derived from a human histiocyic lymphoma. MT-4 is a human T-cell lymphoblast line. Dg-75, 
Raji, and Daudi are Burkitt's lymphoma cell lines. KM H2 is a human Hodgkin's lymphoma cell line. CMK is a megakaryocytic DS. K562 is a chronic myeloid 
leukemia (CMK) cell line. MEG-01 is a megakaryoblastic cell line. 697 is pre-B ALL cell line. Nalm-6 and REH are human precursor leukemia cell lines.BMC Molecular Biology 2007, 8:109 http://www.biomedcentral.com/1471-2199/8/109
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the others. These results imply that there is a certain level
of transcriptomic instability of the TIF-IA locus in certain
cancer cells, in particular leukemic. The definition of
exon/intron is abnormal for the TIF-IA locus, and perhaps
other loci as well, in these cancer cells; what is defined as
an intron for normal tissues is selected as an exon in
leukemic cells.
The wild-type TIF-IA gene is one step away from 
exonization
To understand the molecular mechanisms leading to
exonization in locus 21, but not in loci 15 and 28, we
compared the genomic sequence of the L2-Alu among the
loci (Figure 2B). Many point mutations have accumulated
in the L2-Alu genomic sequence following the duplication
event. One of these mutations was of particular interest,
because it changed a GAG found in locus 15 and 28 to
CAG in locus 21. This CAG is used as the 3'ss of the L2-
AEx. GAG is a week 3'ss, whereas CAG is a strong one [49].
We, thus, hypothesized that this mutation leads to locus
21-specific exonization.
To examine this hypothesis, we cloned a mini-gene con-
taining the human genomic DNA from exon 1 to exon 2
of locus 15 (WT gene). The mini-gene was transfected into
human 293T cells, RNA was extracted, and the splicing
pattern between exon 1 and 2 was examined by RT-PCR
analysis using primers that are specific to the mini-gene
mRNA. As expected the WT mini-gene does not exhibit
Alu-exonization (Figure 4B, lane 2). However, a single
point mutation at position -3 (G → C) at the putative 3'ss
activated the exonization (Figure 4B, lane 3). The predom-
A single point mutation activates the L2-AEx in wild-type TIF-IA Figure 4
A single point mutation activates the L2-AEx in wild-type TIF-IA. (A) A schematic description of the TIF-IA mini-gene cloned into pEGFP-C3 
vector, which contains the human genomic sequence from exon 1 to 2 of locus 15. The sequences of the splice sites are shown below. (B) The WT mini-
gene and the indicated mutants were transfected into 293T cells. Cytoplasmic RNA was extracted and splicing products were separated on 1.5% agarose 
gel after RT-PCR analysis, using primers specific for the mini-gene RNA. The mRNA isoforms are shown on the right; the difference between the two 
upper products is due to alternative 5' splicing of the L2-AEx. (C) Similar analysis to panel B. Position -3 of the 3'ss was mutated from G to each of the 
other three nucleotides. (D) Different selection of the L2-AEx among cells. Transfection of TIF-IA mini-gene with a G → C mutation at position -3 of the 
3'ss of the L2-AEx to seven different cell lines (the name of each cell line is indicated above the lane). The four splicing products are illustrated on the right. 
From bottom to top are: L2-AEx skipped isoform, selection of 5'ss-b Alu-containing exon, intron retention isoform, and unspliced mRNA. U2OS is a 
human-bone-osteosarcoma epithelial cell line. Du145 is a prostate-cancer cell line. HT1080 is a fibrosarcoma cell line. HepG2 is a hepatoma cell line. HeLa 
cells are human epithelial cells from a fatal cervical carcinoma. PC3 is a prostate cancer cell line and 293T is a human-embryonic-kidney cell line.BMC Molecular Biology 2007, 8:109 http://www.biomedcentral.com/1471-2199/8/109
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inant mRNA generated following this mutation is the one
that includes the L2-AExs (selection of 5'ss-b), leading to
a low level of the normal mRNA. In addition, the 3'ss
mutation also generated an intron retention isoform. This
indicates that the L2-Alu in the wild-type gene (locus 15)
is one mutation away from exonization. If such a muta-
tion were to occur, it would terminate production of a
normal TIF-IA protein in the cells almost completely,
because the L2-AEx inserts a premature stop codon.
We next evaluated the effect of 5'ss strength on exoniza-
tion. Strengthening of the either of the two sites did not
activate the exonization (Figure 4B, lanes 4 and 5) and
neither did strengthening both (Figure 4B, lane 8). When
the 3'ss is functional, the selection of 5'ss-a or 5'ss-b is
determined by their relative strength (Figure 4B, lanes 6,
7, and 9). Overall, these results indicate that the L2-Alu
element in the WT TIF-IA gene is on the edge of exoniza-
tion and that a single point mutation from G to C in posi-
tion -3 of the putative 3'ss leads to exonization.
Next, we examined which nucleotides in position -3 of the
3'ss would activate exonization. We mutated the 3'ss from
GAG to CAG, TAG, and AAG (Figure 4C, lanes 1, 2, and 3,
respectively). Only the mutation from G to C at position -
3 lead to exonization: The mutations to A and T did not.
These results support our previous observation that CAG
is the strongest 3'ss [49]. Also, the results show that alter-
native splicing is delicately balanced and is partially con-
trolled by the strength of the 3' and 5'ss signals.
Alternative splicing is often regulated in a tissue-specific
or developmental-stage-specific manner. A common
explanation for differential splicing patterns is that the
concentrations of splicing regulatory proteins vary
depending on tissue type and developmental stage. There-
fore, we examined the effect of different cellular environ-
ments on the splicing of the TIF-IA mini-gene by
transfection into different cell lines; we used the mini-
gene containing the G-to-C mutant at position -3 of the
3'ss. The patterns of splicing observed depended on the
cell line (Figure 4D). In two cell lines, Du145 and PC3,
the introns were not always excised (Figure 4D, lanes 2
and 6, respectively; see figure legend for the source of each
cell line) and in U2OS, HT1080, HepG2, HeLa, and 293T
cell lines, the alternatively spliced mRNA containing L2-
AEx was the predominant isoform (lanes 1, 3, 4, 5, and 7,
respectively). These findings show that, for this TIF-IA
mini-gene, the cellular environment regulates the level of
exonization and intron/exon recognition.
Alu-exonization in YY1AP, the duplicate of GON4Lb
To further support the bioinformatics analysis we demon-
strated another case of a gene that underwent a duplica-
tion event, and the duplicate gene exhibits a distinct
alternative splicing pattern originated from an intronic
Alu element, which also exist in the ancestor gene, but is
not exonized. Figure 5 demonstrates the genomic struc-
ture of the original GON4Lb gene compared to the dupli-
cated gene, YY1AP1 [38]. An intronic Alu  element is
exonized between exons 13 and 14 (Fig. 5A). Aligning the
Alu element in both original and duplicated genes uncov-
ers many sequence changes between them (Fig. 5B). In
contrast to the TIF-IA gene, no mutation was detected in
the splice signals, thus we assume that the reason for
exonization in the duplicated gene and not in the original
GON4Lb gene is due to mutations in regulatory sequences
such as ESRs [50]. Figure 5C examines the splicing pattern
of the corresponding genomic region and revealed that
the Alu element in GON4Lb gene is not exonized while
the duplicated gene (YY1AP1) exhibits low levels of
exonization. When the Alu-exon enters into the mature
RNA of YY1AP1, it inserts a pre-mature termination
codon (PTC) [51]. This strengthened our bioinformatics
analysis showing a second example of exonization that is
found in the duplicated gene and not in the original copy.
Discussion
Gene duplication and alternative splicing are two mecha-
nisms that enhance genome and transcriptome complex-
ity. Gene duplication works at the level of DNA and
alternative splicing at the level of mRNA. These two proc-
esses are seemingly independent, but recent comprehen-
sive bioinformatics analyses suggest that they are
correlated inversely [7,31]. That is, certain genes prolifer-
ate and acquire new functions by duplication, while other
genes gain new functional properties through alternative
splicing.
It was observed previously that duplicated genes, unlike
singletons, undergo relaxation in selective pressure. The
duplicate rapidly diverges from the original sequence due
to a higher rate of nucleotide substitutions within the cod-
ing regions relative to orthologs [9,36]. Here we show that
there is another contributor to the fast divergence of
duplicated genes: a higher level of exonization of trans-
posed elements in duplicated genes relative to singletons.
Previous work dealing with the correlation between alter-
native splicing and gene duplications indicated that there
is less alternative splicing in duplicated genes and that
there is alternative splicing loss after duplication [31,34].
All together our observations imply that although in gen-
eral there is a reduction in alternative splicing in gene fam-
ilies, the level of TEs exonization is higher in duplicated
genes.
In the analysis described here, we found that, following
duplication, genes can acquire new alternatively spliced
isoforms through exonization of transposed elements and
that genes with more than one copy per genome (dupli-BMC Molecular Biology 2007, 8:109 http://www.biomedcentral.com/1471-2199/8/109
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cated genes) tend to undergo more exonization of TE ele-
ments in one of the duplicates than do singletons. This
indicates a high level of selection against exonization in
singletons, with fewer restrictions against exonizations in
multi-copy genes. It also supports the observation that
one of the duplicates is under lower selective pressure,
which allows the accumulation of mutations leading to
exonization without deleterious effects on the organism.
Our results suggest that alternatively spliced exons that
originate from exonization of transposed elements are
found significantly more frequently in duplicated genes
than in singletons. We selected one of these duplicated
genes, TIF-IA, for further examination. TIF-IA underwent a
humanoid-specific triplication, in which one of the dupli-
cates retained the evolutionary conserved exon-intron
structure and maintained the reading frame. Because the
two duplicates were under less evolutionary constraint,
each underwent substantial changes with respect to the
original copy. These changes include large and small dele-
tions and point mutations in the original coding
sequence. In addition, in one of the duplicates, we identi-
TheGON4Lb gene and its duplicate YY1AP1 Figure 5
TheGON4Lb gene and its duplicate YY1AP1. (A) Schematic representation of the genomic organization of GON4Lb 
and YY1AP1. Start codons and stop codons are marked with black arrows and stop signs, respectively. Insertion of an Alu-exon 
to the transcript of YY1AP1 insert a premature termination codon (PTC) (B) Multiple alignment of the alternative Alu-exon of 
YY1AP1 and the relative intronic region of GON4L. Splice sites are marked with black arrows. Substitutions and deletions rel-
ative to the original gene are marked in pink. (C) Exonization of an Alu exon in YY1AP1, and not in the original gene, as shown 
by RT-PCR analysis of U2OS cell line. Primers were designed to the flanking exons of each copy.BMC Molecular Biology 2007, 8:109 http://www.biomedcentral.com/1471-2199/8/109
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fied an exonization of an Alu element that was inserted
into the first intron prior to the duplication. All three cop-
ies of TIF-IA gene are active transcriptionally, but the wild-
type gene is the major contributor to TIF-IA mRNA levels.
Only the wild-type mRNA is translated into protein. We
found negligible levels of this exonization in diverse nor-
mal tissues and diverse cell lines, with the exception of the
293T and BJ-1 cell lines (Figure 3A). In contrast, when we
examined various leukemia cell lines, we discovered high
levels of L2-Alu-exonization in 13 of the 17 cell lines. This
indicates that the definition of this Alu  as an exon is
restricted to certain types of cancers. The genomic
sequence of the Alu between the cells that show exoniza-
tion and those that do not is unchanged (not shown).
This implies that this exonization is due to aberrant
expression or activity of one or more splicing factors.
Next, we generated a mini-gene with the genomic region
of locus 15, the original copy of TIF-IA gene. The single
product of this wild-type mini-gene was the one that
joined exon 1 with exon 2; the Alu element was intronic.
Introducing a single point mutation at position -3 of the
3'ss (from G to C) in the Alu element strengthened the 3'ss
[49]. The main spliced isoform in this mutant was the one
in which 5'ss-b was selected. Alternative splicing of Alu
exons usually generates both the isoform containing the
additional exon and the original isoform that presumably
holds an important function in the cell. Thus, alternative
exonization with low inclusion level can advance tran-
scriptomic diversification. We previously demonstrated
that alternatively spliced Alu exons have low inclusion lev-
els (10–19%) [52]. This strongly suggests that a point
mutation that strengthened the Alu element 3'ss were to
occur in the original gene of TIF-IA (locus 15), there
would be a substantial decrease in the amount of the evo-
lutionary conserved protein. Under these conditions, a
genetic disease might develop [46].
TIF-IA (locus 15) is a vital gene [46], however its two
duplicates (loci 28 and 21) are probably non-functional
based on their relative short open reading frames and very
low expression levels. This duplication probably repre-
sents the non-functional stage described by Ohno in the
period of time following the duplication event. As
described by Ohno, this initial phase of non-functionali-
zation will be followed by complete relaxation of selective
constraints and may be followed by a neo-functionaliza-
tion process, wherein the duplicate acquires a new func-
tion [8,53]. The NCF1 gene duplicates may also be in the
non-functional stage as its two well-described pseudo-
genes are presumably non-functional [43].
Why might there be selective forces against acquisition of
the exons in certain genes and others not? We have dem-
onstrated recently that conserved human-mouse alterna-
tive exons that disrupt the reading frame (termed non-
symmetrical) tend to undergo fixation in the beginning of
the gene, whereas those in the middle and the 3' half of
the genes were presumably "weeded out" during evolu-
tion [51]. This suggests that acquisition of new exons close
to the beginning of the genes is tolerated. In contrast,
those in other parts of the genes are deleterious because
polypeptides translated from these mRNAs are less likely
to be targeted for the nonsense mediated decay than
shorter products and the exon-containing isoforms are
likely to be deleterious to the cells. If the initial exoniza-
tion is natural or even present beneficial advantages to the
cells, it will lead to an increase in the inclusion level of
these alternative exons [54]. The mutation in the 3'ss of
the L2-AEx in TIF-IA gene (locus 15) presumably occurred
during evolution in some individuals, but was selected
against since TIF-IA is a vital gene, this isoform must have
been deleterious due to the insertion of a premature ter-
mination codon.
Conclusion
Our results add another layer to our understanding of the
delicate interplay between gene duplication and alterna-
tive splicing. Both increase gene complexity, albeit
through different mechanisms. We have demonstrated an
indirect link between duplication of genes and exoniza-
tion of transposed elements. Duplicated genes, especially
the non-functional, tend to undergo exonization more
than singletons.
Methods
Dataset of TE exons in human and mouse genomes
We compiled a dataset of TE exonizations within protein
coding genes [28]. The human NCBI 35 (hg17, May 2004)
and the mouse NCBI33m (mm6, March 2005) assemblies
were downloaded, along with their annotations, from the
UCSC genome browser database [55]. Coordinates of the
EST and cDNA mapping were obtained from
chrN_intronEST and chrN_mrna tables, respectively. The
TE mapping was obtained from chrN_rmsk tables. A TE
was considered intragenic if there was no overlap with
ESTs or cDNA alignments; it was considered intronic if it
was found within an alignment of an EST or cDNA within
an intronic region. Finally, a TE was considered exonic if
it was found within an exonic part of the EST or cDNA, if
it possessed canonical splice sites, and if it was an internal
exon of the EST/cDNA found within the CDS or a UTR.
The insertions of TEs within EST/cDNA alignments were
separated into two parts: those that entered within protein
coding genes relative to the list of the knownGene table in
the UCSC genome browser [55] (based on proteins from
SWISS-PROT, TrEMBL, TrEMBL-NEW and their corre-
sponding mRNA from GenBank), and other insertions
within cDNA/ESTs alignments that were not mapped to
the known genes list and, therefore, were considered asBMC Molecular Biology 2007, 8:109 http://www.biomedcentral.com/1471-2199/8/109
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non-protein-coding genes. Non-protein-coding genes
were determined as genomic regions covered by at least
two correctly spliced cDNA/ESTs (flanked by canonical
splice sites) containing at least three exons that did not
overlap any annotated gene based on UCSC known genes
lists, versions hg17 and mm6 for human and mouse,
respectively. Unspliced genes were not included in our
analysis; we only considered genes with at least two
introns. Internal UTR exons were considered to be inter-
nal according to the annotations of knownGenes in UCSC
and the fact that they were internal within the cDNA/EST.
The TE position within the gene (UTR or CDS) and the
exon phase were calculated based on knownGenes table
annotations of the gene start and end positions, as well as
CDS start and end positions.
TE exonization within duplicated genes
To analyze whether the exonization occurred within a
duplicated gene or a singletons, we performed a blast
search of these genes against all mRNA sequences listed as
known genes (knownGene table) downloaded from
UCSC human genome build hg17 [55] and searched for
transcripts with at least 75% sequence similarity along 40
percent of the gene, the dataset was filtered to delete tran-
scripts of isoforms generated by alternative splicing that
belonged to the same gene and nonduplicated genes. The
filtration of similar mRNA that are isoforms of the same
gene was done by comparing the locus of the mRNA as
indicated in UCSC genome browser; only mRNAs that
mapped to different loci were considered.
Cell line maintenance
293T, HeLa, HT1080, HepG2, Du145, and U2OS cell
lines were cultured in Dulbecco's Modification of Eagle
Medium (DMEM), supplemented with 4.5 g/mL glucose
(Biological Industries, Inc., Israel), 10% fetal calf serum
(FCS), 100 U/mL penicillin, 0.1 mg/mL streptomycin,
and 1 U/mL nystatin (Biological Industries, Inc.). PC3
cells were cultured in Ham's F12K medium with 2 mM L-
glutamine adjusted to contain 1.5 g/L sodium bicarbonate
(90%) and fetal bovine serum (10%). Cells were grown in
6-well plates or 100-mm culture dishes under standard
conditions at 37°C with 5% CO2. Cells were split at a 1:10
ratio twice weekly.
Transfection
Cells were grown to 50% confluence in 100-mm culture
dishes or 6-well plates and maintained as described
above. Twenty-four hours prior to transfection, cells were
split, and transfection was performed using FuGENE6
(Roche) with 0.5–1 μg of plasmid DNA. Cells were har-
vested after 48 hr.
RNA isolation and splicing analysis
Total RNA was extracted using TRI Reagent (Sigma), fol-
lowed by treatment with 2 U of RNase-free DNase
(Ambion). Reverse transcription (RT) was performed on
1–2 μg total RNA in a 12.5 μL final volume containing:
100 mM DTT, 10 mM dNTPs, 100 mM oligo(dT) primer,
2 U of reverse transcriptase avian myeloblastosis virus
(RT-AMV, Roche), and RT buffer. The final mixture was
then incubated for 1 hr at 42°C. The spliced cDNA prod-
ucts derived from the expressed mini-genes were detected
by PCR, using Taq polymerase (BioTools), and pEGFP-C3
specific reverse and forward primers. Primer sets for cell-
line scanning purposes were designed to amplify all loci
in a single PCR or to amplify every locus separately: 3 loci:
5'-CGT TAG TTC GGC CCA ATG-3', 5'-CTT CAG CAA
GAC TTC TGT CAC-3'; locus 15: 5'-CTT CGT CCT CTG
CAG TTA AGA AG-3', 5'-CTT CAG CAA GAC TTC TGT
CAC-3'; locus 28: 5'-CGC TTC GCC CTC TGC AGT C-3',
5'-CTT CAG CAA GAC TTC TGT CAC-3' after reverse tran-
scription (RT) with unique primer; locus 21: 5'-CTT CAC
ACG TTG TTT GTC G-3', 5'-CTT CAG CAA GAC TTC TGT
CAC-3'. Amplification of the chimpanzee cDNA (prolifer-
ating blood cells of a female chimpanzee from the safari
in Ramat-Gan) was performed with 5'-CGT TAG TTC
GGC CCA ATG-3' and 5'-GCT GGT TCT TCA ACA ACT
CAA A-3'. The primers flank the Alu element in intron 1 of
the TIF-IA's genes. Human GAPDH: 5'-TCG TGG AGT
CCA CTG GCG TCT T-3' and 5'-TGG CAG TGA TGG CAT
GGA CTG T-3'. Chimp GAPDH: 5'-TCG TGG AGT CCA
CTG GCG TCT T-3' and 5'-TGG CAG TGA TGG CAT GGA
CCG T-3'. GON4L: 5'-ATG AGC TGA TGG AAG AGC TG-
3' and 5'-GAG GGG TGT TAA AGT TAG GAC GAG-3'.
YY1AP1: 5'-CAA ATG AGC TGA TGG AAG AT-3' and 5'-
GAG GGG TGT TAA AGT TAG CTT-3'. Amplification was
performed for 30 cycles, consisting of denaturation for 30
seconds at 94°C, annealing for 45 seconds at 58°C, and
elongation for 1.5 minutes at 72°C. The products were
separated in 1.5% agarose gel; selected bands were con-
firmed by sequencing.
Plasmid construct
A genomic DNA from 293T cell line (Gentra) correspond-
ing to exon 1 through exon 2 of the TIF-IA gene (from
locus 15) was PCR amplified and cloned into pEGFP-C3
vector (Clontech) between XhoI and BamHI sites under
the control of the human cytomegalovirus (CMV) imme-
diate early promoter, giving a ~1.9 kb insert. F: 5'-AAA
AAA ACT CGA GGC TGA TTG GCT GAA GGT TG-3'; R: 5'-
AAA AGG ATC CCA GCA ATA GTT GTA TTC TGA CCT
AAC C-3'.
Site-directed mutagenesis
Specific overlapping oligonucleotide primers that con-
tained the desired mutation were used to insert the muta-
tion using PfuTurbo DNA polymerase (Stratagene). AfterBMC Molecular Biology 2007, 8:109 http://www.biomedcentral.com/1471-2199/8/109
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PCR amplification, the reaction was digested with DpnI
restriction enzyme (New England Biolabs) for 1 hr at
37°C; 1–3 μL of the reaction were transformed into E. coli
XL-1 strain and colonies were picked for mini-prep extrac-
tion (Qiagen) and sequenced. L2-AEx-3'ss (-3)G->C: 5'-
GAA GAC ATC TGT CAT TTC AGC TTC CAC TTG AAT G-
3' and 5'-CAT TCA AGT GGA AGC TGA AAT GAC AGA
TGT CTT C-3'. L2-AEx-3'ss (-3)G->T: 5'-GAA GAC ATC
TGT CAT TTT AGC TTC CAC TTG AAT G-3' and 5'-CAT
TCA AGT GGA AGC TAA AAT GAC AGA TGT CTT C-3'. L2-
AEx-3'ss (-3)G->A: 5'-GAA GAC ATC TGT CAT TTA AGC
TTC CAC TTG AAT G-3' and 5'-CAT TCA AGT GGA AGC
TTA AAT GAC AGA TGT CTT C-3'. L2-AEx-5'ss-a (5)C->G:
5'-CAT GGT GGC AGG TGC GTG TAA TCC CAG CTA C-
3' and 5'-GTA GCT GGG ATT ACA CGC ACC TGC CAC
CAT G-3'. L2-AEx-5'ss-b (-1)A->G: 5'-GTA TTT CCA ATA
GAG TGA ACG GTA AGT GAA ATG AAA AAC AGC-3' and
5'-GCT GTT TTT CAT TTC ACT TAC CGT TCA CTC TAT
TGG AAA TAC-3'.
Western blotting
Lysis buffer (50 mM Tris, pH 7.5; 1% NP40; 150 mM
NaCl; 0.1% SDS; 0.5% deoxycholic acid; protease inhibi-
tor cocktail and phosphatase inhibitor cocktail I and II;
Sigma) was used for protein extraction. Then lysates were
centrifuged for 30 minutes at 14,000 rpm at 4°C. Total
protein concentrations were measured using BioRad Pro-
tein Assay (BioRad). Proteins were separated in 10% SDS-
polyacrylamide gel electrophoresis (SDS-PAGE) and then
electroblotted onto a Protran membrane (Schleicher and
Schuell). The membranes were probed with polyclonal
anti-TIF-IA antibody (kindly provided by Ingrid Grummt)
at 1/10000 dilution followed by rabbit secondary anti-
body. Immunoblots were visualized by enhanced chemi-
luminescence (Lumi-Light Western Blotting Substrate;
Roche) and exposure to x-ray film.
Transposed elements analysis
RepeatMasker© software version 3.1.0 [56] was used for
the detection of transposed elements.
Analysis of the relative mRNA levels
The PCR product from RT-PCR of P69 cells was excised
and purified following electrophoresis on 1.5% agarose
gel (Promega, Madison, WI, USA). Direct sequencing was
performed using the ABI PRISM (Applied Biosystems, Fos-
ter-City, CA, USA). The variation percentage from direct
sequencing was calculated for the reverse primer; the pre-
sented percentages represent an average of three separated
positions (31, 63 and 105) along exon 2 of the mRNAs.
The nucleotides were quantified by the Discovery Studio
(DS) Gene 1.5 program (Accelrys Inc., San Diego, CA,
USA).
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